Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Human CellExpCD4, human recombinant protein
CD4, CD-4, CD4mut, CD-4mut
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P01730 |
|---|---|
| Calculated MW | This protein rhCD4 is fused with Fc fragment of human IgG1 at the C-terminus, has a calculated MW of 68 kDa expressed. The predicted N-terminus is Lys26. Protein migrates as 80 kDa in reduced SDS-PAGE due to glycosylation. |
| Gene ID | 920 |
|---|---|
| Gene Symbol | CD4 |
| Other Names | CD4, CD-4, CD4mut, CD-4mut |
| Gene Source | Human |
| Source | HEK 293 cells |
| Assay&Purity | SDS-PAGE; ≥98% |
| Assay2&Purity2 | N/A; |
| Recombinant | Yes |
| Results | Measured by its ability to bind with HIV-1 gp120 in a functional ELISA. |
| Target/Specificity | CD4 |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in PBS, pH 7.4. Do not vortex. |
| Format | Lyophilized |
| Storage | -20°C; Lyophilized from 0.22 µm filtered solution in 50 mM Tris, 100 mM glycine, pH 7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Cluster of Differentiation 4 (CD4), also known as T-cell surface antigen T4/Leu-3 (LEU-3) and CD4mut, is a single-pass type I membrane glycoprotein, and is a member of the immunoglobulin superfamily. CD4 expressed on the surface of T helper cells, monocytes, macrophages, and dendritic cells. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell: D1 and D3 resemble immunoglobulin variable (IgV) domains. D2 and D4 resemble immunoglobulin constant (IgC) domains. CD4 is a co-receptor that assists the T cell receptor (TCR) with an antigen-presenting cell. Using its portion that resides inside the T cell, CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as the tyrosine kinase lck, which is essential for activating many molecules involved in the signaling cascade of an activated T cell. CD4 also interacts directly with MHC class II molecules on the surface of the antigen-presenting cell using its extracellular domain. The extracellular domain adopts an immunoglobulin-like beta-sandwich with seven strands in 2 beta sheets, in a Greek key topology. CD4 has also been shown to interact with SPG21, Lck and Protein unc-119 homolog. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.
References
Maddon P.J.,et al.Cell 42:93-104(1985).
Littman D.R.,et al.Cell 55:541-541(1988).
Ansari-Lari M.A.,et al.Genome Res. 6:314-326(1996).
Ansari-Lari M.A.,et al.Genome Res. 7:268-280(1997).
Hodge T.W.,et al.Hum. Immunol. 30:99-104(1991).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
